dm+d

Unassigned

New Medicines

Lewy body and Parkinson's disease dementia

Information

New molecular entity
Eisai
Eisai

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Phosphodiesterase 9 inhibitor
Incidence and prevalence figures vary widely, but a recent review in the UK found the incidence to be around 4% of new cases of dementia. It found DLB to account for 4.2% of all cases of dementia diagnosed in the community, and 7.5% of those diagnosed in secondary care [1].
Lewy body and Parkinson's disease dementia
Oral